Menu Search
Equities

Vertex Pharmaceuticals Inc

VX1:STU

Vertex Pharmaceuticals Inc

Actions
  • Price (EUR)262.05
  • Today's Change2.90 / 1.12%
  • Shares traded30.00
  • 1 Year change72.33%
  • Beta--
Data delayed at least 15 minutes, as of May 22 2020.
More ▼

Profile data is unavailable for this security.

About the company

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

  • Revenue in USD (TTM)4.82bn
  • Net income in USD1.51bn
  • Incorporated1989
  • Employees3.00k
  • Location
    Vertex Pharmaceuticals Inc50 Northern AveBOSTON 02210-1862United StatesUSA
  • Phone+1 (617) 341-6393
  • Websitehttps://www.vrtx.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		VRTX:NSQ since
announced		Transaction
value
Semma Therapeutics IncAnnounced03 Sep 201903 Sep 2019Announced58.29%950.00m
Exonics Therapeutics IncDeal completed06 Jun 201906 Jun 2019Deal completed64.46%1.05bn
Data delayed at least 15 minutes, as of May 22 2020 21:00 BST.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.